Filed for bankruptcy in Jan 2025
SEEL - Seelos Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
SEEL price evolution
SEEL
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.29 | $0.52 | $3 | $2.58 |
| Short term investments | ||||
| Net receivables | $0.19 | $0.97 | $0.76 | $0.22 |
| Inventory | ||||
| Total current assets | $2.33 | $3.55 | $5.4 | $6.19 |
| Long term investments | ||||
| Property, plant & equipment | $0.05 | $0.06 | $0.01 | $0.03 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.05 | $0.06 | $0.01 | $0.03 |
| Total investments | ||||
| Total assets | $2.38 | $3.61 | $5.42 | $6.22 |
| Current liabilities | ||||
| Accounts payable | $15.69 | $15.27 | $16.4 | $9.32 |
| Deferred revenue | ||||
| Short long term debt | $10.16 | $13.14 | $14.23 | $15.6 |
| Total current liabilities | $30.51 | $36.72 | $38.93 | $35.33 |
| Long term debt | $1.3 | |||
| Total noncurrent liabilities | $1.3 | |||
| Total debt | $10.16 | $13.14 | $14.23 | $16.91 |
| Total liabilities | $30.51 | $36.72 | $38.93 | $36.63 |
| Shareholders' equity | ||||
| Retained earnings | -$253.58 | -$255.29 | -$252.63 | -$247.17 |
| Other shareholder equity | ||||
| Total shareholder equity | -$28.13 | -$33.1 | -$33.51 | -$30.41 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3 | $15.53 | $78.73 | $15.66 |
| Short term investments | ||||
| Net receivables | $0.76 | |||
| Inventory | ||||
| Total current assets | $5.4 | $22.67 | $83.46 | $17.49 |
| Long term investments | ||||
| Property, plant & equipment | $0.01 | $0.07 | $0.04 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.01 | $0.07 | $0.04 | |
| Total investments | ||||
| Total assets | $5.42 | $22.75 | $83.5 | $17.49 |
| Current liabilities | ||||
| Accounts payable | $16.4 | $3.63 | $1.69 | $1.89 |
| Deferred revenue | ||||
| Short long term debt | $14.23 | $11.92 | $1.07 | $2.43 |
| Total current liabilities | $38.93 | $25.16 | $8.29 | $7.43 |
| Long term debt | $8.18 | $17.89 | $7.29 | |
| Total noncurrent liabilities | $8.2 | $17.89 | $7.49 | |
| Total debt | $14.23 | $20.12 | $18.96 | $9.72 |
| Total liabilities | $38.93 | $33.36 | $26.18 | $14.92 |
| Shareholders' equity | ||||
| Retained earnings | -$252.63 | -$214.74 | -$141.21 | -$75.16 |
| Other shareholder equity | ||||
| Total shareholder equity | -$33.51 | -$10.61 | $57.32 | $2.57 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.38 | $0.58 | $0.65 | $0.41 |
| Cost of revenue | ||||
| Gross Profit | $0.38 | $0.58 | $0.65 | $0.41 |
| Operating activities | ||||
| Research & development | $0.97 | $3.52 | $5.92 | $10.02 |
| Selling, general & administrative | $2.55 | $3.11 | $2.75 | $2.99 |
| Total operating expenses | $3.52 | $6.63 | $8.66 | $13.01 |
| Operating income | -$3.14 | -$6.05 | -$8.01 | -$12.6 |
| Income from continuing operations | ||||
| EBIT | $1.73 | -$2.64 | -$5.43 | $10.54 |
| Income tax expense | ||||
| Interest expense | $0.02 | $0.02 | $0.02 | $0.04 |
| Net income | ||||
| Net income | $1.71 | -$2.66 | -$5.45 | $10.5 |
| Income (for common shares) | $1.71 | -$2.66 | -$5.45 | $10.5 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.2 | |||
| Cost of revenue | ||||
| Gross Profit | $2.2 | |||
| Operating activities | ||||
| Research & development | $30.12 | $58.62 | $46.65 | $10.98 |
| Selling, general & administrative | $12.59 | $12.3 | $15.02 | $7.78 |
| Total operating expenses | $42.7 | $70.92 | $61.67 | $18.76 |
| Operating income | -$40.5 | -$70.92 | -$61.67 | -$18.76 |
| Income from continuing operations | ||||
| EBIT | -$37.81 | -$73.52 | -$64.45 | -$18.94 |
| Income tax expense | ||||
| Interest expense | $0.07 | $0.01 | $1.6 | $0.16 |
| Net income | ||||
| Net income | -$37.88 | -$73.53 | -$66.05 | -$19.1 |
| Income (for common shares) | -$37.88 | -$73.53 | -$66.05 | -$19.1 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $1.71 | -$2.66 | -$5.45 | $10.5 |
| Operating activities | ||||
| Depreciation | $0.01 | $0.01 | $0.01 | $0.01 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.87 | $0.95 | $0.96 | $0.97 |
| Total cash flows from operations | -$0.97 | -$4.64 | -$1.91 | -$5.75 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.93 | $3.48 | $4.48 | $4.38 |
| Net borrowings | -$0.18 | -$1.31 | -$2.15 | -$1.89 |
| Total cash flows from financing | $0.74 | $2.17 | $2.32 | $2.49 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.23 | -$2.47 | $0.41 | -$3.26 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$37.88 | -$73.53 | -$66.05 | -$19.1 |
| Operating activities | ||||
| Depreciation | $0.06 | $0.05 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.99 | $5.07 | $8.35 | $2.04 |
| Total cash flows from operations | -$23.91 | -$61.6 | -$48.99 | -$20.91 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $19.02 | $0.56 | $105.42 | $15.26 |
| Net borrowings | -$7.64 | -$1.89 | $6.65 | $11.05 |
| Total cash flows from financing | $11.38 | -$1.6 | $112.07 | $26.31 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$12.54 | -$63.2 | $63.07 | $5.4 |
News
Fundamentals
| Market cap | $66.44K |
|---|---|
| Enterprise value | $9.93M |
| Shares outstanding | 3.32M |
| Revenue | $2.01M |
|---|---|
| EBITDA | $4.26M |
| EBIT | $4.20M |
| Net Income | $4.09M |
| Revenue Q/Q | 11.90% |
| Revenue Y/Y | 76.05% |
| P/E ratio | 0.02 |
|---|---|
| EV/Sales | 4.93 |
| EV/EBITDA | 2.33 |
| EV/EBIT | 2.37 |
| P/S ratio | 0.03 |
| P/B ratio | -0.00 |
| Book/Share | -8.47 |
| Cash/Share | 0.09 |
| EPS | $1.23 |
|---|---|
| ROA | 92.82% |
| ROE | -13.07% |
| Debt/Equity | -1.16 |
|---|---|
| Net debt/EBITDA | 7.10 |
| Current ratio | 0.08 |
| Quick ratio | 0.08 |